Signals of symptom benefit or symptom burden can be included early in the development of a drug to guide the development of dosing recommendations and needed supportive care and to inform potential providers and patient consumers along with those who must approve the agent and those who will determine whether or not to pay for it. == Future perspective == A number of converging factors in the development of agents to treat hematological malignancies indicate that characterization of the symptomatic status of patients in response to new agents will increase in importance in the next 510 years. in hematological clinical trials. Keywords:malignancy clinical trials, drug development, European Medicines Agency, patient-reported outcomes, recommendations, symptom assessment, symptom burden, symptom benefit, US FDA The survival of patients with hematological malignancies has been significantly extended by a rapid growth in the availability of new brokers, including tyrosine kinase inhibitors, proteasome inhibitors and monoclonal antibodies targeted to hematopoietic cell surface markers. As a result of increased understanding of the molecular basis of hematological diseases, many of which were rapidly fatal in the past, these diseases are becoming chronic, with indefinite periods of remission so long as treatment is usually managed [1]. These gains have broadened our view of the outcomes of therapy to include how patients feel and function during extended periods of survival. Given an increasing number of therapies with similar survival outcomes, maintenance of better functioning with fewer treatment-related symptoms becomes an increasing therapeutic advantage, and COTI-2 information about symptomatic status and function obtained in clinical trials is COTI-2 helpful to both patients and their healthcare team in treatment decision making. There is increasing acknowledgement that identification of symptoms sensitive to changes in disease and to the effects of treatment is usually important in oncology practice and clinical research. Symptoms are subjective phenomena reported by patients and indicating change in normal functioning, sensation or appearance due to disease and treatment [2]. When treatment only marginally extended survival, life-threatening toxicities were the major concern in making decisions about the acceptability of therapy; however, these toxicities were measured by clinician ratings and did not capture patients experience during therapy. Patient-reported outcome (PRO) measures most directly portray patients views of the impact of treatment on how they are feeling and functioning. Methodologically sound patient self-report is a critical component of drug evaluation [35]. == The evolution of patient report: a brief history == In the 1970s, the concept of individual quality of life (QOL) began to appear in the oncology literature. Factors identified as being part of QOL measurement have consistently included daily functioning and symptoms as well as other factors such as general health, emotional well-being and cost [6,7]. Although QOL was recognized as reflecting a patients experience, direct assessment by patient report was not sought. QOL was evaluated by objective events, such as hospitalizations, or was subjectively rated by clinicians [8]. Initially, QOL concerns were primarily related to radical surgeries or intensive therapies, such as those for acute leukemia [8,9]. The idea of measuring QOL in clinical trials was advanced in the early 1980s [10]. The focus was on determining if one treatment offered a QOL advantage over another equally efficacious regimen. During this period, results of quantitative clinician assessments of patient functionality were reported [11], patients were asked to judge the quality of their lives [12], and the ideas of operationally defining QOL for COTI-2 uniform measurement and the need to measure QOL longitudinally for a complete understanding of the impact of treatment were introduced [7]. During the 1990s, efforts were made to overcome the obstacles associated with QOL measurement in oncology populations and especially in clinical trials. By this time, patient report was identified as the optimal source of information about Rabbit Polyclonal to MAPKAPK2 (phospho-Thr334) QOL and the concept of QOL was narrowed to focused on health-related QOL (HRQOL) in an effort to remove extraneous factors that had nothing to do with disease or treatment [13]. Critical HRQOL issues for patient care are managing symptoms and maintaining functionality [14]. Several oncology-specific measures of HRQOL were developed and became widely used, enabling comparisons of results across clinical trials [1518]. The value of establishing the psychometric reliability and validity of assessment instruments became more widely understood COTI-2 and accepted. By 2000, the need for reliable HRQOL clinical trial end points to guide the practicing clinician in patient discussion of treatment options was recognized [14]. Although HRQOL is a narrower concept than QOL, it nonetheless includes broad domains that may be affected by many factors beyond a single disease and its treatments [13]. Early in the 2000s, symptoms and the.